CRL vs NKTX · rev $2.00B vs $188.9M cap
Charles River Laboratories (CRL) versus Nkarta Inc (NKTX) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Nkarta Inc (NKTX) is a biotechnology company listed on NASDAQ.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
Latest reported NKTX revenue for 2025-12-31 was $0. Net income was -$104.1M. NKTX currently screens at market cap $188.9M.
CRL currently screens at market cap $7.78B. NKTX currently screens at market cap $188.9M.
Not investment advice. Open the CRL and NKTX stock pages for the full models.
Not investment advice.